Neuroimmunology & Multiple Sclerosis — Specialty Profile

Exploratory, not prescriptive. This profile blends hard data (pay, match rates, burnout, demographics, each sourced and dated) with generalizations and synthesized opinion about culture and "who fits." It's here to help you get curious and go find out for yourself, not to tell you who to become. Numbers marked ⟳ verify change every year; check the linked source before you quote one. Last reviewed: 2026-08-04.

Also called: MS and neuroimmunology, MS/NI, neuroimmunology, multiple sclerosis. A 1-year fellowship entered after a neurology residency, without ACGME accreditation or a board certificate. Organ system: the central nervous system, when the immune system attacks it.

Subspecialty fellowship of Neurology.

The 30-second version

A multiple sclerosis specialist can generate more than eight million dollars a year for their institution and be paid less than a general neurologist. That gap is the defining fact of this field, and it has been measured. A 2017 analysis put one full-time MS specialist's potential downstream revenue at $29.2 million a year if every study and infusion were done in-house, with roughly $8.4 million as the realistic figure at one academic center, against an academic neurologist salary near $177,000. The mechanism is simple: the value sits in MRI scans and in disease-modifying drugs that cost $60,000 to $100,000 a year each, while the neurologist is paid for office visits. Meanwhile the clinical story is the best in neurology. A disease that had no treatment at all before 1993 had twenty approved therapies by 2021 and has added more since, and the field has gone from managing decline to preventing it. The trade at the center: neurology's most treatable disease, a documented workforce shortage, no board certificate, and a payment system that counts none of what the work is actually worth.

Quick dashboard (details and sources below)


Training after med school	5 years (1 intern year + 3 yr neurology residency + 1 yr MS/NI fellowship)
Total from college start	~13 years (4 undergrad + 4 med school + 4 residency + 1 fellowship)
Training chain	Med school (4) → Neurology (4) → 1-yr MS/neuroimmunology fellowship → no board certificate
Competitiveness	Low. About 69 programs against a documented subspecialist shortage ⟳
Typical full-time pay	Below general neurology. Parent neurology runs ~$340,000–$362,000 ⟳
Pay vs. parent (general neurology)	Below, because the practice is E&M-based with almost no procedural revenue ⟳
Lifestyle	Outpatient, clinic-dominant, light call, heavy administrative load ⟳
Burnout	No subspecialty figure; parent neurology 44% in Medscape 2024, below the 49% all-physician average ⟳
% women	No subspecialty figure; parent neurology 33% practicing, 50.2% of residents ⟳
DO / IMG accessibility	Good: 18.8% DO and 22.4% IMG of neurology's 999 filled PGY-1 positions in 2026 ⟳

What they actually do

Multiple sclerosis is the anchor, and it affects close to a million Americans.¹ The practice is diagnosis, treatment selection from a crowded field of drugs, monitoring for both disease activity and drug toxicity, and the management of symptoms that no disease-modifying therapy touches.

Choosing the therapy is the intellectual core of the job. The twenty disease-modifying therapies approved as of 2021, and those approved since, differ in efficacy, route, monitoring burden, pregnancy compatibility, infection risk, and cost, and the field has moved decisively toward starting high-efficacy treatment early rather than escalating after failure.² Getting that choice right in a thirty-year-old with a new diagnosis shapes the next four decades of their life.

Neuromyelitis optica spectrum disorder and MOGAD are the diseases the field separated out from MS, and getting the distinction right matters enormously, because some MS drugs make NMOSD worse. Both now have their own targeted therapies.

Autoimmune encephalitis is the fastest-moving part of the practice. A set of antibody-mediated syndromes that were being diagnosed as psychiatric disease twenty years ago are now recognized, treatable, and frequently reversible.

The rest of the practice: optic neuritis, transverse myelitis, neurosarcoidosis, CNS vasculitis, paraneoplastic neurologic syndromes, and the neurologic complications of the immunotherapies other specialties now prescribe.

Symptom management is the half that patients feel most. Spasticity, fatigue, bladder dysfunction, neuropathic pain, gait, and cognition, none of which respond to the drugs that modify the disease.

The insurance work is a genuine and unglamorous part of the job. Drugs at this price require prior authorization, appeals, and step-therapy navigation, and the specialist is the person writing those letters.

Representative work: diagnosis and long-term management of multiple sclerosis · disease-modifying therapy selection, sequencing, and monitoring · NMOSD and MOGAD diagnosis and targeted treatment · autoimmune and paraneoplastic encephalitis · optic neuritis and transverse myelitis · neurosarcoidosis and CNS vasculitis · MRI interpretation for disease activity · management of infusion therapies · pregnancy planning on immunotherapy · spasticity, fatigue, bladder, pain, and cognitive symptom management · prior authorization and appeals.¹

A day in the life: almost entirely outpatient. Long new-patient visits, follow-ups built around MRI review, infusion-center oversight, and a substantial block of unbillable time on authorizations, appeals, and patient messages. Many MS specialists work in dedicated MS centers with nursing, rehabilitation, and social work alongside them.

On call: light. Acute relapses and new encephalitis presentations arrive, but this is not a specialty defined by nights.

The training path & time to completion

Medical school (4 yrs) → neurology residency (1 intern year + 3 yrs) → 1-year MS and neuroimmunology fellowship → no board certificate exists.¹

There are about 69 MS and neuroimmunology fellowship programs in the United States, which is a large number for a subspecialty with no accreditation.¹ ⟳
Training splits into clinical and clinical-research tracks, and the consensus curriculum deliberately avoids mandating a fixed duration so programs can fit individual career goals.¹
There is no accreditation and no certificate. The field's own consensus curriculum states plainly that the subspecialty has not sought accreditation previously, while noting growing interest among programs and proposing the curriculum as a basis for future accreditation.¹
The curriculum was written against ACGME core competencies even though no ACGME accreditation exists, which is a field building the scaffolding before the building.¹
Total from the start of college: about 13 years.

Why the consensus curriculum exists. Its authors name a shortage: not enough MS and neuroimmunology subspecialists, with anticipated future shortfalls compounding the problem, against a disease affecting nearly a million Americans that requires specialized expertise for accurate diagnosis and optimal management.¹ Standardizing training without an accreditor is what a field does when demand is outrunning it.

How competitive is it?

The fellowship is not competitive. Roughly 69 programs exist and the field publicly describes itself as short of subspecialists.¹ ⟳
The upstream residency is moderately competitive, filling at 99.6% in 2026, with DOs taking 18.8% and international graduates 22.4% of the 999 PGY-1 positions that filled.³ ⟳
There is no board examination, so no diplomate count, no pass rate, and no certified workforce census exists for this field. ⟳
Demand is structural and growing. MS is a disease of young adults that people live with for decades, the treatment landscape now requires genuine expertise to navigate, and the patient population is not shrinking.¹

The honest read. Anyone finishing neurology who wants this can get it. The competition is for the well-known MS centers, where the research and the referral base are.

Board: none. ABPN certification in neurology is the only board credential an MS specialist holds.¹

Compensation — the robust version

The gap between what an MS specialist earns and what their work is worth to the institution employing them has been quantified. Berger puts one specialist's downstream revenue at 10.36 times their compensation, or 6.21 once adjusted for clinical effort.⁴

The parent anchor. General neurology runs roughly $340,000–$362,000.³ ⟳

What the field itself earns. AMN Healthcare's Neurologist Salary Report 2025 places MS specialists near $267,000 on average, with new graduates around $210,000, below the parent field. Those are a recruiting firm's placement figures rather than survey lines, and the direction is consistent with everything below.⁵ ⟳

The downstream revenue analysis. A 2017 study in Neurology: Clinical Practice modelled what one full-time MS specialist generates for an academic health center. If every diagnostic study, disease-modifying therapy, and consultation were captured in-house, the figure was $29,247,450 a year. Accounting for real-world insurance and convenience constraints, the estimate at the University of Pennsylvania was approximately $8,377,463 a year. Against an academic neurologist salary of about $177,000 in 2014 data, that is a revenue-to-compensation ratio of 10.36, or 6.21 once adjusted for clinical effort.⁴ ⟳

Where the money is. MRI scans at diagnosis and follow-up, and the drugs. Disease-modifying therapies average on the order of $60,000 a year, and under the 340B drug pricing program institutions received 58% more than the cost of the drug, which the same analysis put at roughly $2,900 per patient per month in institutional profit.⁴ ⟳

Why none of it reaches the physician. MS care is labor-intensive and billed almost entirely through evaluation and management codes. There is no procedure. The patient education, the treatment selection, and the hours spent on prior authorization generate no relative value units at all while producing the downstream revenue above.⁴ A compensation model built on RVUs will systematically underpay this work, and it does.

Drug prices are the context for all of it. The first disease-modifying therapy was approved in 1993 at an annual cost of $19,509 in 2020 dollars. Oral therapy list prices rose from $73,924 to $104,372 between 2013 and 2021, with net prices going from $69,187 to $82,181.² ⟳

Limited-data caveat: the revenue analysis is a single-center model from 2017 and the salary figures are aggregator estimates rather than survey lines. The direction is well supported and the magnitudes should be checked. If you are negotiating, the Berger analysis is the document to bring. ⟳

Lifestyle

Among the better lifestyles in neurology, and one of the most purely outpatient practices in the specialty.
Clinic-dominant and schedulable, built around long visits and MRI review.
Call is light, without the stroke and status epilepticus burden that shapes general neurology call.
The administrative load is heavy and unbillable, dominated by prior authorization and appeals.
Infusion oversight adds structure rather than unpredictability.
Geographic flexibility is moderate. MS centers concentrate at academic and larger community institutions, though MS patients exist everywhere.
The relationships are long. People are diagnosed young and followed for decades.

Lifestyle rating: 4/5. Outpatient, predictable, and light on emergencies, deducted for a paperwork burden that is genuinely large and entirely uncompensated.

Wellbeing — the part to take seriously

No subspecialty-specific figure was located. Inherit parent neurology, which Medscape's 2024 report puts at 44%, below the 49% all-physician average and among the lowest ten of the twenty specialties that report ranks.³ ⟳

The therapeutic optimism here is real and it separates this field from most of neurology. Neurology has a reputation for diagnosing what it cannot treat. MS is the counterexample: twenty drugs, measurable disease control, and patients whose lives look substantially different from what they would have in 1990. Practitioners cite this constantly.

The insurance fight is the counterweight and it is corrosive. Prescribing a $70,000 drug means arguing with a payer about it, often repeatedly, often annually, and the physician is the person who does that arguing. It is uncompensated, it is time-consuming, and the consequence of losing is a patient going without treatment that works.

Progressive disease remains the field's limit. The therapies work well against relapsing disease and much less well against progressive accumulation of disability, and following a patient into secondary progression is following them somewhere the drugs largely cannot go.

The population is young, which cuts both ways. Diagnosing a twenty-eight-year-old with a lifelong neurologic disease is a hard conversation, and the same fact means the physician sees decades of a person's life.

The undervaluation grinds on people over time. Knowing that your clinic funds the department's imaging suite and infusion center while your salary sits below general neurology is a specific and recurring form of professional frustration, and the field publishes about it.

Who's in the field (demographics)

No subspecialty-specific demographic data was located, which is the recurring consequence of having no board: there is no diplomate registry to count. Inherit neurology.

Women: parent neurology runs 33% of practicing physicians (2022 data) and 50.2% of residents (AY2024-25), a spread that reflects who trained twenty years ago rather than any disagreement between the two counts.³ ⟳
DO: 18.8% of the 999 neurology PGY-1 positions that filled in 2026.³ ⟳
IMG: 22.4% of the same 999 filled positions, down from 29.1% in the 2025 cycle.³ ⟳
The patient population is disproportionately women, which is a feature of the disease rather than of the workforce, and it shapes the practice around pregnancy planning and family decisions on immunotherapy in a way few neurology subspecialties require. ⟳
Underrepresented in medicine: no subspecialty figure. MS outcomes differ substantially by race and access, Black Americans have historically been underdiagnosed and are now recognized to have more aggressive disease on average, and a $60,000-a-year drug is rationed by insurance status more than by need. ⟳
Programs: about 69, against a shortage the field names in print.¹ ⟳

Culture, personality & the online stereotypes

Who gravitates here: neurology residents who wanted to treat rather than to localize. The field draws people who like immunology, who are comfortable with complex drug selection and long relationships, and who are willing to fight insurers routinely. It is academic, research-heavy, and unusually collaborative, partly because the disease moves fast enough that everyone is learning. As always, plenty of people in the field do not fit any single mold.

The stereotypes. Community perception rather than fact, each with a kernel and an unfair edge:

"The one neurology subspecialty where you actually fix people." Overstated and closer to true than for most of the specialty.
"You are a prior authorization clerk with a fellowship." Unfair and recognizable to everyone in the field.
"MRI interpretation is half your job." Substantially accurate.
"You generate millions and take home a neurologist's salary." Documented rather than folklore.⁴

What people say online (synthesized and paraphrased, not quotes): across trainee and physician forums, MS reads as the most rewarding clinical work in the specialty and the most administratively exhausting. The dominant recurring theme is the therapeutic revolution, described by people in the field with genuine enthusiasm. A second is insurance, raised constantly and bitterly. A third is compensation, discussed with reference to the downstream revenue analysis specifically, which is unusual for an internet argument. A fourth is the missing board, treated as a minor practical issue and a real signal about how the specialty is valued. The tone is enthusiastic about the medicine and angry about the economics.

Voices from the field. Paraphrased from published sources, with links to the originals:

The 2021 consensus curriculum reports 69 MS and neuroimmunology fellowship programs in the United States, states that the subspecialty has not sought accreditation previously, and proposes itself as a basis for future accreditation, citing a shortage of subspecialists against a disease affecting nearly a million Americans.¹
Berger's 2017 analysis estimates one full-time MS specialist's potential downstream revenue at $29,247,450 annually, roughly $8,377,463 in realistic practice at one academic center, against academic neurologist compensation near $177,000, and argues that RVU-based models cannot capture E&M-dependent MS care.⁴

Why people choose it / why people leave

Why choose it: the most treatable major disease in neurology, transformed within a career · twenty therapies and a field that keeps changing · long relationships with patients diagnosed young · an outpatient, low-call practice · a documented shortage, which is job security · immunology as the intellectual core · autoimmune encephalitis, one of the most satisfying diagnoses in medicine.

Why leave or avoid it: pay below general neurology despite generating enormous institutional revenue · a prior authorization burden that is large, constant, and unpaid · no board certificate and no accreditation · progressive disease the drugs cannot reach · a practice with essentially no procedural income · dependence on MS centers for the best jobs.

Best fit if: immunology and complex drug selection appeal · you want to treat rather than to diagnose · long outpatient relationships suit you · you can absorb administrative friction without it embittering you · you want a field still changing quickly.

Not for you if: you want procedural income · insurance fights would grind you down · you need a board certificate · you want acute, high-stakes neurology.

The FLI angle — Neuroimmunology & MS for first-gen, low-income & immigrant students

Where it fits FLI realities well:

Neurology takes DO and international graduates in numbers, 18.8% and 22.4% of the 999 PGY-1 positions filled in 2026, and this fellowship is undersubscribed against a named shortage.¹³ Both doors are genuinely open.
PSLF fits well, because MS centers sit at academic and nonprofit institutions and the training years count.
The lifestyle is sustainable, outpatient and low-call, which matters if you are supporting family.
The patients are rationed by insurance, visibly. A $60,000-a-year drug means access tracks coverage rather than need, and Black Americans have historically been underdiagnosed while having more aggressive disease on average. A physician who understands how people fall through those gaps changes outcomes here in a concrete way.

Risks to name honestly:

This subspecialty pays less than the residency it comes from. That is unusual and you should confront it directly: an extra year leading to a practice below general neurology's $340,000–$362,000.³ If you carry large debt without family support, model that year explicitly.
The value you create will not be yours. The published analysis is a physician generating roughly $8.4 million for an institution while paid a fraction of a percent of it.⁴ Some people find that argument useful in negotiation and others find it demoralizing over twenty years. Know which you are.
No board means no portable credential. Your standing comes from where you trained and who knows you, which puts weight on networks that FLI trainees often have to build from nothing.
The administrative burden is real work that nobody pays for, and it falls hardest on physicians serving patients with the worst insurance, which is to say the patients you may most want to serve.

Bottom line for FLI: an open door at both steps, a sustainable outpatient career, and the most genuinely effective treatment in neurology, at the cost of an extra year that pays negatively and a structural undervaluation the field has documented about itself. If the medicine is what draws you, this is a good life. Go in with the Berger analysis in hand and negotiate against it rather than around it.

Fun facts

One full-time MS specialist was estimated to generate up to $29.2 million a year in downstream revenue for an academic health center, and about $8.4 million in realistic practice, against a salary near $177,000.⁴
Under the 340B drug pricing program, institutions received 58% more than the cost of a disease-modifying therapy, roughly $2,900 per patient per month in profit.⁴
Multiple sclerosis had no disease-modifying treatment at all before 1993. Twenty had been approved by 2021, and more have followed since.²
The first of those drugs cost $19,509 a year in 2020 dollars. Oral therapies now list above $100,000.²
The field has about 69 fellowship programs and no accreditation of any kind, and it wrote its own consensus curriculum against ACGME competencies anyway.¹
Some drugs that treat multiple sclerosis make neuromyelitis optica worse, which is why separating the two diagnoses correctly is one of the highest-stakes distinctions in the field.

Sources

Fellowship structure, program count, accreditation status, and workforce. Hua LH, Obeidat AZ, Amezcua L, et al. "Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology." Neurology: Clinical Practice. 2021;11(4):352–357. doi:10.1212/CPJ.0000000000001040 — identifies 69 MS and NI fellowship programs in the United States; describes clinical and clinical-research tracks without mandating fixed durations; states that the subspecialty has not sought accreditation previously while noting growing interest among training programs and proposing the curriculum as a basis for future accreditation; built against ACGME core competencies; cites insufficient numbers of MS and NI subspecialists with anticipated future shortages, against a disease affecting nearly one million Americans; defines core competency in MS, NMOSD, MOGAD, optic neuritis, and myelitis, and in the appropriate use of immunotherapies and symptomatic management. https://pmc.ncbi.nlm.nih.gov/articles/PMC8382436/ ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵
Disease-modifying therapy landscape and pricing. Hartung DM. "Health economics of disease-modifying therapy for multiple sclerosis in the United States." Therapeutic Advances in Neurological Disorders. 2021 — twenty FDA-approved disease-modifying therapies differing by route of administration; the first, interferon beta-1b, was approved in 1993 at an annual cost of $19,509 in 2020 dollars. https://journals.sagepub.com/doi/10.1177/1756286420987031. Corrected 2026-08-17: the count of twenty is Hartung's, published in 2021, and this page had been stating it as a present-day total. At least one further therapy has been approved since — ublituximab (Briumvi), FDA-approved for relapsing forms in December 2022 — and no authoritative current count was found, so the figure is now dated rather than replaced. Price trend from "Changes in List and Net Prices for Multiple Sclerosis Disease-Modifying Therapy, 2013 to 2021," Neurology: Clinical Practice — oral DMT list prices rose from $73,924 to $104,372 and net prices from $69,187 to $82,181. https://www.neurology.org/doi/10.1212/CPJ.0000000000200597 ⟳ ↩ ↩² ↩³ ↩⁴
Parent-field figures for neurology. Typical comp ~$340k–$362k: see the neurology profile on this site. Burnout 44%, against an all-physician average of 49%, and among the ten lowest of the twenty specialties the report ranks: Medscape Physician Burnout & Depression Report 2024, n=9,226, fielded July–October 2023, paywalled and returning HTTP 402, so it reaches this page through Healthgrades Pro (https://resources.healthgrades.com/pro/the-most-and-least-burned-out-physicians-by-specialty), which prints neurology's row inside its ten least burned-out list, and Advisory Board (https://www.advisory.com/daily-briefing/2024/01/31/physician-burnout), which prints the 49% all-physician figure. Corrected 2026-08-17: this page had called parent neurology "elevated" with "sources ranging from roughly 44% to 55%". The 44% is Medscape's and sits five points below its own all-physician average; the upper half of that range was attributed to field-synthesis reporting that named no instrument and no survey, so it is removed rather than re-sourced. Women in practice, 33%: AAMC, "Women are changing the face of medicine in America" (2022 data), https://www.aamc.org/news/women-are-changing-face-medicine-america. Women in training: ACGME, Data Resource Book, Academic Year 2024-2025, Table C.21, https://www.acgme.org/globalassets/pfassets/publicationsbooks/2024-2025_acgme_databook_document.pdf, which puts neurology residents at 50.2% women in academic year 2024-25. Correction 2026-08-13: this page previously carried ~40% of neurology residents, in the Quick dashboard and in Who's in the field. Fill rate, DO and IMG shares: NRMP, Results and Data: 2026 Main Residency Match, May 2026, Table 2, https://www.nrmp.org/wp-content/uploads/2026/05/Main_Match_Results_and_Data-2026.pdf, which reports neurology 99.6% filled on 1,003 positions offered and 999 filled, with DO seniors and graduates taking 188 of those 999 (18.8%) and US plus non-US international graduates taking 224 (22.4%). Corrected 2026-08-17: this page carried ~16.5% DO and ~29% IMG from the 2025 cycle, and the pair was internally inconsistent as well as stale — 16.5% is DO seniors alone over positions offered (154/932) while ~29% includes both IMG types (269/925). On one denominator, positions filled including graduates, the two cycles read DO 17.0% → 18.8% and IMG 29.1% → 22.4%, so the DO share rose and the IMG share genuinely fell. Swept 2026-08-17: verified against Table 2 and unchanged. All eleven profiles in the neurology family now state 18.8% DO and 22.4% IMG on this denominator. The all-PGY-1 baselines from the same totals row are 21.5% DO and 25.2% IMG of 38,354 filled positions, which places neurology just under the ordinary rate on both axes. ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸
Downstream revenue and the RVU critique. Berger JR. "The financial contribution of the multiple sclerosis specialist." Neurology: Clinical Practice. 2017;7(3):246–255 — estimates that one full-time MS specialist could generate $29,247,450 annually if all diagnostic studies, disease-modifying therapies, and consultations occurred within the academic health center, with approximately $8,377,463 as the estimate at the University of Pennsylvania given insurance and convenience constraints; against academic neurologist compensation of about $177,000 (2014 data), revenue-to-compensation ratios of 10.36, or 6.21 adjusted for clinical effort; estimates average DMT expense on the order of $60,000 annually, with institutions receiving 58% more than drug cost under Medicare 340B pricing, roughly $2,900 per patient per month; argues that RVU models inadequately capture labor-intensive, E&M-dependent MS care including patient education and insurance authorization that generate no RVUs. https://pmc.ncbi.nlm.nih.gov/articles/PMC6081969/ ⟳ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹
The subspecialty's own pay figures. AMN Healthcare, Neurologist Salary Report 2025 — multiple sclerosis specialists average $267,000, with new graduates starting at $210,000, against adult neurology's $244,000 average and neuro-oncology's $341,000 in the same report. https://www.amnhealthcare.com/blog/physician/perm/neurologist-salary-report-2025/ — a recruiting firm's placement and base-oriented figures rather than a physician survey, which is why they sit below the total-compensation surveys this page quotes for the parent field. Corrected 2026-08-17: the $267,000 and $210,000 pair previously appeared as unattributed "aggregator figures" with no footnote marker, on the one sentence the page's pay argument needs. ⟳ ↩

Researched with AI assistance and reviewed by hand. How this site is made